Sunesis withdraws vosaroxin MAA for AML

Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) said it will withdraw an MAA from EMA for Qinprezo vosaroxin (AG-7352) to treat relapsed or refractory acute myelogenous leukemia (AML) in patients ages ≥60. Sunesis said the agency's CHMP “was likely to formally adopt a negative opinion in its evaluation of the application.”...